Form 10-K GALECTIN THERAPEUTICS For: Dec 31

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. META
5. SPY
6. ANT
7. INTC
8. JBLU
9. NVDA
10. AAPL

Go back to Form 10-K GALECTIN THERAPEUTICS For: Dec 31

Galectin Therapeutics (GALT) Tops Q4 EPS by 3c

March 15, 2016 7:43 AM EDT

Galectin Therapeutics (NASDAQ: GALT) reported Q4 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22).

Management Commentary

Numerous clinical advancements during 2015 with our lead compound GR-MD-02 form the basis for a productive 2016, and we look forward to reporting on a number of important development milestones throughout the year, said Peter G. Traber, M.D., president, chief executive officer and chief medical officer of Galectin Therapeutics. Of particular note, during 2015 we began two Phase 2 studies with GR-MD-02 in non-alcoholic steatohepatitis, or NASH, a disease that has been gaining considerable awareness not only among clinicians,... More